Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Shares Issued: 2019-2025

Historic Shares Issued for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to $257,000.

  • Allogene Therapeutics' Shares Issued fell 62.15% to $257,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 60.95%. This contributed to the annual value of $1.5 million for FY2024, which is 38.50% down from last year.
  • Allogene Therapeutics' Shares Issued amounted to $257,000 in Q3 2025, which was up 102.74% from -$9.4 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Shares Issued high stood at $10.0 million for Q1 2025, and its period low was -$9.4 million during Q2 2025.
  • Moreover, its 3-year median value for Shares Issued was $765,000 (2023), whereas its average is $703,714.
  • As far as peak fluctuations go, Allogene Therapeutics' Shares Issued plummeted by 100.03% in 2022, and later soared by 1,068.46% in 2025.
  • Allogene Therapeutics' Shares Issued (Quarterly) stood at $322,000 in 2021, then grew by 24.13% to $931,000 in 2022, then fell by 17.83% to $765,000 in 2023, then decreased by 11.24% to $679,000 in 2024, then slumped by 62.15% to $257,000 in 2025.
  • Its Shares Issued stands at $257,000 for Q3 2025, versus -$9.4 million for Q2 2025 and $10.0 million for Q1 2025.